Intec Pharma Operating Income

Intec Pharma (NTEC) currently reports a operating income of $-14M as of March 2021. That compares with $-26M in the prior-year period — up 46.1% year over year. Use the charts on this page to explore Intec Pharma's operating income history and peer comparisons.

Intec Pharma's operating income increased from $-26M to $-14M — a 46.1% year-over-year increase (period ending March 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intec Pharma reported $-14M in operating income as of March 2021. That compares with $-26M in the prior-year period — up 46.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intec Pharma, and consider following NTEC for alerts when major investors trade the stock.

Intec Pharma is classified in the Healthcare sector. On operating income, it currently shows $-14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NTEC with unrelated industries.